All the authors vouch for the precision and completeness of the info and the fidelity of the analysis to the protocol. Statistical Analysis We estimated that 2456 patients would have to undergo randomization at the 200 study centers to ensure a minimum of 2234 sufferers who could be evaluated in order to supply the study with a power of 90 percent to determine the noninferiority of the hazard ratio for exacerbation among patients in the glucocorticoid-withdrawal group, in comparison with the glucocorticoid-continuation group, with a one-sided alpha degree of 0.025 and an expected dropout rate of 15 percent each year. The assumed median period to the first principal event was 9 weeks. The prespecified noninferiority margin of 1 1.20 was defined as the upper limit of the 95 percent self-confidence interval for the hazard ratio for the initial average or severe exacerbation in the glucocorticoid-withdrawal group, as compared with the glucocorticoid-continuation group.Corresponding estimates of remission rates at week 52 for the most efficient vedolizumab program in the trial of maintenance therapy had been 30 percent and 50 percent. The planned enrollment of 375 patients in the trial of induction therapy and 372 individuals in the trial of maintenance therapy supplied at least 90 percent power to detect distinctions with an alpha mistake of 5 percent.5,16 Outcomes Baseline and Randomization Features In total, 1406 individuals were evaluated for eligibility ; 895 were included and signed up for the analysis, of whom 58 did not meet one or more inclusion criteria or met one or more exclusion criteria .